Latest News
AGM Chairman address and CEO presentation
Nov 20th, 2020
Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.
Read More
SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray
Nov 19th, 2020
Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.
Read More
Quarterly Cashflow and Activities Report
Oct 30th, 2020
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2020.
Read More
Completion of Placement and SPP raises $48.9M in total
Oct 29th, 2020
Starpharma today announced that it has completed its Share Purchase Plan (SPP), raising $3.9 million. The SPP was conducted in conjunction with Starpharma’s recent institutional placement (Placement), which together have raised a total of $48.9 million. The issue of 2.6 million new shares under the SPP will be at $1.50 per share, being equivalent to the Placement share price.
Read More